AiwuRuthHeMD

Oncology • Washington, DC

Associate Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. He is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. He's full profile

Already have an account?

Office
3800 Reservoir Rd Nw
Washington, DC 20007
Phone+1 202-444-2198

Summary

I am a board certified medical oncologist focus on GI cancer.

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 2004 - 2006
Hunan Medical UniversityClass of 1991

Certifications & Licensure

DC State Medical License 2004 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer Start of enrollment: 2008 Nov 01
Unknown status
Phase 1
Sunitinib and Capecitabine for First Line Colon Cancer Start of enrollment: 2009 Aug 01
Terminated
Phase 2
ABT-888 and Temozolomide for Liver Cancer Start of enrollment: 2010 Aug 01
Terminated
Phase 2
A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
Completed
Phase 2
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron Start of enrollment: 2017 Jul 05
Terminated
Phase 2
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis Start of enrollment: 2018 Aug 09
Active, not recruiting
Phase 1
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Nov 30
Terminated
Phase 2
Roles: Principal Investigator, Contact, Sponsor-Investigator
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma Start of enrollment: 2024 Jun 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

304 citations
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka
NEJM Evidence. 2022-08-01
254 citations
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling
Yi Tang, Krit Kitisin, Wilma Jogunoori, Cuiling Li, Chu-Xia Deng
Proceedings of the National Academy of Sciences of the United States of America. 2008-02-19
349 citations
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Michael S. Lee, Baek Yeol Ryoo, Chih-Hung Hsu, Kazushi Numata, Stacey Stein
The Lancet. Oncology. 2020-06-01

Press Mentions

SPTBN1 Inhibits Inflammatory Responses and Hepatocarcinogenesis via the Stabilization of SOCS1 and Downregulation of p65 in Hepatocellular CarcinomaFebruary 20th, 2021